Блог
Последни новини, научни статии и полезна информация за молекулярната онкологична диагностика и персонализираната терапия.
Roferon-a (F. Hoffmann-La Roche) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key market opportunities for Roferon-A include its growing adoption in oncology and personalized immunotherapy, driven by rising cancer incidence and healthcare expenditure. Increased drug approvals and an expanding focus on combination therapies boost market…
The Cancer Immunotherapy Revolution: From Artificial Sweeteners to T-Cell Monitoring
Recent discoveries in cancer immunotherapy reveal new factors that may affect patients’ treatment response and help researchers improve these outcomes.
These Genetically Engineered Brain Cells Devour Toxic Alzheimer’s Plaques
A single shot protected mice from the protein gunk implicated in Alzheimer's disease. The post These Genetically Engineered Brain Cells Devour Toxic Alzheimer’s Plaques appeared first on SingularityHub.
Cornell study finds existing drug could boost liver cancer immunotherapy
Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cor...
FDA OKs Perioperative Immunotherapy for Stomach Cancer
Durvalumab significantly reduced the risk of death in a phase III trial
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type …
Страница 2 от 13 • Общо 75 статии